Latest Regulatory Milestones News

DP World Australia has secured Foreign Investment Review Board approval to acquire 100% of Silk Logistics, clearing a major regulatory hurdle for the deal.

High-Tech Metals has obtained crucial mining approvals and formed a joint venture to tap into historic gold stockpiles at its Mt Fisher Project, aiming for early cash flow and resource definition.

Imagion Biosystems has received encouraging feedback from the FDA on its MagSense HER2 breast cancer imaging program, clearing the path for a Phase 2 clinical trial and fast-tracking manufacturing.

EBR Systems has received preliminary approval from the U.S. Centers for Medicare & Medicaid Services for outpatient reimbursement of its WiSE® CRT System, marking a major step toward broader hospital adoption.

Star Minerals has made significant strides in developing its Tumblegum South Gold Project, signing a key MOU with MEGA Resources and completing a $1.6 million capital raise to support upcoming mining activities.

Imugene Limited reports promising Phase 1b trial results for azer-cel, an off-the-shelf CAR T therapy, showing a 75% overall response rate in relapsed diffuse large B-cell lymphoma patients. The company plans to engage the FDA later this year to discuss pivotal trial design.

VBX Limited has successfully listed on the ASX and revealed strong preliminary feasibility results for its Wuudagu Bauxite Project, positioning itself to capitalize on rising bauxite demand and supply uncertainties.

Osteopore Limited has gained Swiss market approval for its 3D-printed bioresorbable implants under the EU Medical Device Regulation, completing its European product portfolio and strengthening its partnership with Zimmer Biomet.

Victory Metals has secured critical U.S. federal government approval, enabling direct engagement with the Department of Defence and access to substantial funding to advance its heavy rare earths project in Western Australia.

Tyranna Resources has agreed to acquire a 70% interest in the Maongo Copper-Gold Project in Angola, marking a strategic expansion into demand-driven metals with promising historical mining activity and strong infrastructure access.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing of Elate Ocular, a promising treatment for moderate to severe dry eye disease, pending additional financing.

Coda Minerals has submitted the Draft Scoping Report for its Elizabeth Creek Copper-Cobalt Project, marking a pivotal step in securing mining lease approvals in South Australia. This milestone reduces regulatory uncertainty and sets a clear path toward project development.